Author

L. J. Medeiros

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:clustering· 1 Assay:DNA methylation· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. Khanna· 1 shared C. Bueso-Ramos· 1 shared E. B. Roarty· 1 shared E. Jabbour· 1 shared F. Darbaniyan· 1 shared F. Ravandi· 1 shared F. Sloulidis· 1 shared G. Garcia-Manero· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Khanna

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

R. Kanagal-Shamanna, G. Montalban-Bravo, K. Sasaki, E. Jabbour, C. Bueso-Ramos, Y. Wei, K. S. Chein, T. M. Kadia, F. Ravandi, G. M. Borthakur, K. A. Soltysiak, N. G. Daver, F. Darbaniyan, M. Routbort, K. Patel, , G. Garcia-Manero

This study shows that SF3B1 mutations specifically at codon K700E, but not other codons, are independently linked to better overall survival in myelodysplastic syndromes.

bioRxiv · Sep 4, 2020Cancer Biology

Simplified Molecular Classification of Lung Adenocarcinomas Based on EGFR, KRAS, and TP53 Mutations

R. Ruiz-Cordero, J. Ma, A. Khanna, G. Lyons, W. Rinsurongkawong, R. Bassett, M. Guo, M. J. Routbort, J. Zhang, F. Sloulidis, J. V. Heymach, E. B. Roarty, Z. Tang, L. J. Medeiros, K. P. Patel, , S. Roy-Chowdhuri

This paper classifies lung adenocarcinomas into six subtypes based on EGFR, KRAS, and TP53 mutations, finding associations with prognosis and validating the classification against clinical outcomes.

bioRxiv · Jan 21, 2019Cancer Biology